AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15979441 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 32
Study 15979441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12823608 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and melatonin (20 mg/day orally in the evening)
Number of subjects: 100
Study 12823608 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 100
Study 12823608 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and melatonin
Number of subjects: 100
Study 10672721 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion of the kidney cavitary system with the drug Palisan
Number of subjects: 0
Study 8729614 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (extended fields)
Number of subjects: 316
Study 8729614 — intervention group
Group type: COMPARATOR
Intervention: Combined chemotherapy (CHOP or CHOP-like)
Number of subjects: 316
Study 8729614 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (radiotherapy followed by chemotherapy)
Number of subjects: 316
Study 1923163 — intervention group
Group type: EXPERIMENTAL
Intervention: IV magnesium tocolysis for more than 7 days
Number of subjects: 33
Study 1923163 — intervention group
Group type: COMPARATOR
Intervention: Gestational age-matched unexposed neonates
Number of subjects: 33
Study 6616485 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocardia rubra cell wall skeleton (N‐CWS)
Number of subjects: 309
Study 6616485 — intervention group
Group type: COMPARATOR
Intervention: Control group (local chemotherapy with Adriamycin)
Number of subjects: 309
Study 29332428 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus preoperative preparation (tour, cartoon video, familiarization with medical equipment)
Number of subjects: 0
Study 29332428 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 29643055 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 33
Study 29643055 — intervention group
Group type: EXPERIMENTAL
Intervention: Education+Feedback
Number of subjects: 33
Study 29643055 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study 27136493 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 599
Study 27136493 — intervention group
Group type: EXPERIMENTAL
Intervention: Small changes
Number of subjects: 599
Study 27136493 — intervention group
Group type: EXPERIMENTAL
Intervention: Large changes
Number of subjects: 599
Study 24091902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 31
Study 24091902 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 31
Study 24091902 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 22496199 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (SSRI), 40 mg maximum daily dosage
Number of subjects: 115
Study 22496199 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (SNRI), 225 mg maximum daily dosage
Number of subjects: 115
Study 22496199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 20920046 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of insulin secretagogues
Number of subjects: 964
Study 20920046 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of insulin secretagogues (Control)
Number of subjects: 964
Study 17656354 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with bupivacaine (0.1%) containing fentanyl (2 microg ml(‐1))
Number of subjects: 28
Study 17656354 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia with morphine
Number of subjects: 28
Study 17656354 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups on supplemental oxygen
Number of subjects: 28
Study 16272187 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (2mg)
Number of subjects: 6
Study 16272187 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (3mg)
Number of subjects: 6
Study 11403537 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 0
Study 11403537 — intervention group
Group type: COMPARATOR
Intervention: Higher doses of H(2)-receptor antagonists
Number of subjects: 0
Study 11403537 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (low-dose)
Number of subjects: 0
Study 11403537 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study 11403537 — intervention group
Group type: EXPERIMENTAL
Intervention: PPIs
Number of subjects: 0
Study 9552953 — intervention group
Group type: EXPERIMENTAL
Intervention: READER method of critical appraisal
Number of subjects: 243
Study 9552953 — intervention group
Group type: COMPARATOR
Intervention: Free appraisal
Number of subjects: 243
Study 7846931 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveform
Number of subjects: 33
Study 7846931 — intervention group
Group type: COMPARATOR
Intervention: Monophasic waveform
Number of subjects: 33
Study 7846931 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous anode position in Vena anonyma
Number of subjects: 33
Study 7846931 — intervention group
Group type: COMPARATOR
Intervention: Transvenous anode position in Vena cava superior
Number of subjects: 33
Study 3059850 — intervention group
Group type: EXPERIMENTAL
Intervention: Open challenge with a large dose (3 g/kg) of candy bar sucrose
Number of subjects: 16
Study 3059850 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind challenge test utilizing lemon-flavored slushes of sucrose, honey, tapioca starch, or aspartame
Number of subjects: 16
Study 3059850 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during double-blind challenge)
Number of subjects: 16
Study 4590669 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen
Number of subjects: 60
Study 4590669 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 60
Study 4590669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31640636 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (going to bed 1 hour later than usual for 7 nights)
Number of subjects: 110
Study 31640636 — intervention group
Group type: COMPARATOR
Intervention: Sleep extension (going to bed 1 hour earlier than usual for 7 nights)
Number of subjects: 110
Study 27017207 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP-144-SR (6M) 22.5 mg
Number of subjects: 167
Study 27017207 — intervention group
Group type: COMPARATOR
Intervention: TAP-144-SR (3M) 11.25 mg
Number of subjects: 167
Study 27017207 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP-144-SR (6M)
Number of subjects: 167
Study 27017207 — intervention group
Group type: COMPARATOR
Intervention: TAP-144-SR (3M)
Number of subjects: 167
Study 27190347 — intervention group
Group type: EXPERIMENTAL
Intervention: High-clearance period (PCS: 23 ± 4 mL/min; IS: 30 ± 5 mL/min)
Number of subjects: 14
Study 27190347 — intervention group
Group type: COMPARATOR
Intervention: Low-clearance period (PCS: 12 ± 3 mL/min; IS: 17 ± 4 mL/min)
Number of subjects: 14
Study 27190347 — intervention group
Group type: EXPERIMENTAL
Intervention: High-clearance period
Number of subjects: 14
Study 27190347 — intervention group
Group type: COMPARATOR
Intervention: Low-clearance period
Number of subjects: 14
Study 24375969 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging-assisted lifestyle weight loss intervention (3 group sessions, 5 coaching calls, daily text messages)
Number of subjects: 123
Study 24375969 — intervention group
Group type: COMPARATOR
Intervention: Control group (brief advice session)
Number of subjects: 123
Study 22767972 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-septal suturing
Number of subjects: 697
Study 22767972 — intervention group
Group type: COMPARATOR
Intervention: Merocel packing
Number of subjects: 697
Study 22767972 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 697
Study 19812469 — intervention group
Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 0
Study 19812469 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 0
Study 19812469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19812469 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI-CGIC overall
Number of subjects: 0
Study 19812469 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI-CGIC
Number of subjects: 0
Study 17341532 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 50 mg
Number of subjects: 26
Study 15105190 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid treatment plus moderate acute normovolemic hemodilution (ANH)
Number of subjects: 100
Study 15105190 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid treatment (control group)
Number of subjects: 100
Study 11905977 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-reducing cushion
Number of subjects: 32
Study 11905977 — intervention group
Group type: COMPARATOR
Intervention: Foam cushion
Number of subjects: 32
Study 9255857 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered mood ratings (SIGH-SAD)
Number of subjects: 14
Study 9255857 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered mood ratings (HIGH-SAD)
Number of subjects: 14
Study 9255857 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face mood ratings (SIGH-SAD)
Number of subjects: 14
Study 9255857 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face mood ratings (HIGH-SAD)
Number of subjects: 14
Study 8101467 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine (twice daily)
Number of subjects: 71
Study 8101467 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (four times daily)
Number of subjects: 71
Study 8101467 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine
Number of subjects: 71
Study 8101467 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate
Number of subjects: 71
Study 3098484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PGE1 infusion
Number of subjects: 0
Study 3098484 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study 30518682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Number of subjects: 1997
Study 27450474 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 0.9 mg/kg alteplase plus standard care
Number of subjects: 1948
Study 27450474 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 1948
Study 24435660 — intervention group
Group type: EXPERIMENTAL
Intervention: +1.50‐D executive bifocals
Number of subjects: 135
Study 24435660 — intervention group
Group type: EXPERIMENTAL
Intervention: +1.50‐D executive bifocals with 3‐Δ base‐in prism
Number of subjects: 135
Study 24435660 — intervention group
Group type: COMPARATOR
Intervention: Single‐vision lenses (control)
Number of subjects: 135
Study 22745245 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg daily for 12 weeks
Number of subjects: 22
Study 20332510 — intervention group
Group type: COMPARATOR
Intervention: 2000 trials
Number of subjects: 1135
Study 20332510 — intervention group
Group type: COMPARATOR
Intervention: 2006 trials
Number of subjects: 1135
Study 18971727 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical autologous platelet-rich fibrin
Number of subjects: 20
Study 18971727 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 20
Study 17081460 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical corpectomy with fusion (ACF)
Number of subjects: 84
Study 17081460 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical corpectomy and fusion with preserved posterior vertebral wall (PWCF)
Number of subjects: 84
Study 12651665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (250 microg) with clonidine (25 microg)
Number of subjects: 81
Study 12651665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (250 microg) with clonidine (75 microg)
Number of subjects: 81
Study 12651665 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (250 microg)
Number of subjects: 81
Study 10908006 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix treatment model for methamphetamine abuse
Number of subjects: 169
Study 10908006 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 169
Study 8644689 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola margarine and canola cooking oil
Number of subjects: 23
Study 8644689 — intervention group
Group type: COMPARATOR
Intervention: Control group (second wintering-over group)
Number of subjects: 23
Study 8516522 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of oral omeprazole
Number of subjects: 103
Study 8516522 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of oral omeprazole
Number of subjects: 103
Study 8516522 — intervention group
Group type: COMPARATOR
Intervention: Non-premedicated patients
Number of subjects: 103
Study 8516522 — intervention group
Group type: COMPARATOR
Intervention: Premedicated with lorazepam and meperidine
Number of subjects: 103
Study 3552458 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg penbutolol with 6 mg piretanide
Number of subjects: 20
Study 3552458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29154619 — intervention group
Group type: EXPERIMENTAL
Intervention: List words
Number of subjects: 0
Study 29154619 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical distractors
Number of subjects: 0
Study 29154619 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementarity ratio
Number of subjects: 0
Study 27208120 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota-fermented milk
Number of subjects: 47
Study 27208120 — intervention group
Group type: COMPARATOR
Intervention: Placebo milk
Number of subjects: 47
Study 23318917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using a pulsed 810-nm laser (average power 50 mW, peak power 80 W, 1,500 Hz, 120 s, 6 J, and 3.4 J/cm² per point) applied three times a week for 4 weeks
Number of subjects: 20
Study 23318917 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (same application as LLLT but without energy output)
Number of subjects: 20
Study 23591663 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral nutritional supplement drink containing 1.3 mg of vitamin B2, 1.4 mg of vitamin B6, 1.5 μg of B12, 200 μg of folic acid
Number of subjects: 236
Study 23591663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 19054400 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical ketogenic diet
Number of subjects: 145
Study 19054400 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride (MCT) ketogenic diet
Number of subjects: 145
Study 17301038 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral sleep-wake observation (BOS%)
Number of subjects: 174
Study 17301038 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination score
Number of subjects: 174
Study 17301038 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography (subgroup of 48 participants)
Number of subjects: 174
Study 17301038 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression analysis
Number of subjects: 174
Study 15130301 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD navigation (trial group)
Number of subjects: 58
Study 15130301 — intervention group
Group type: COMPARATOR
Intervention: Routine navigation (control group)
Number of subjects: 58
Study 11781171 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost, interior lead hazard control interventions
Number of subjects: 0
Study 11781171 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 9442415 — intervention group
Group type: EXPERIMENTAL
Intervention: MUSE up to 1000 micrograms
Number of subjects: 103
Study 9442415 — intervention group
Group type: COMPARATOR
Intervention: Intracavernous Alprostadil (Prostavasin) up to 20 micrograms
Number of subjects: 103
Study 7515649 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil/prednisone (ChP)
Number of subjects: 259
Study 7515649 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP
Number of subjects: 259
Study 7515649 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 259
Study 2454376 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25-50 mg)
Number of subjects: 8
Study 2454376 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 8
Study 2454376 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 8
Study 29132880 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (2.5 mg twice a day) plus aspirin (100 mg once a day)
Number of subjects: 7470
Study 29132880 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (5 mg twice a day)
Number of subjects: 7470
Study 29132880 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg once a day)
Number of subjects: 7470
Study 27216406 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg betamethasone orally (n=50)
Number of subjects: 100
Study 27216406 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg betamethasone parenterally (n=25)
Number of subjects: 100
Study 27216406 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=25)
Number of subjects: 100
Study 27216406 — intervention group
Group type: COMPARATOR
Intervention: All groups (oral, parenteral, control)
Number of subjects: 100
Study 25131773 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 64
Study 25131773 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 22572633 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg, p.o.) 24h before administration of radiocontrast agent and hydration (1mg/kg/hN/saline for 12h pre‐ and post‐contrast)
Number of subjects: 159
Study 22572633 — intervention group
Group type: COMPARATOR
Intervention: Hydration alone (1mg/kg/hN/saline for 12h pre‐ and post‐contrast)
Number of subjects: 159
Study 20498270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 75
Study 20498270 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic indices (APED, IVMD, OVERLAP)
Number of subjects: 75
Study 18405150 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (body acupuncture, electroacupuncture, auricular acupoint taping and pressing)
Number of subjects: 80
Study 18405150 — intervention group
Group type: COMPARATOR
Intervention: Medication group (oral administration of Sibutramine)
Number of subjects: 80
Study 16522834 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oral azithromycin
Number of subjects: 515
Study 16522834 — intervention group
Group type: COMPARATOR
Intervention: Untreated villages (control)
Number of subjects: 515
Study 14674809 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants communicated a stereotype-relevant story through 4-person chains.
Number of subjects: 3
Study 10826390 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Maintenance Organization (HMO) option
Number of subjects: 0
Study 10826390 — intervention group
Group type: COMPARATOR
Intervention: Standard CHAMPUS system
Number of subjects: 0
Study 10826390 — intervention group
Group type: EXPERIMENTAL
Intervention: HMO option
Number of subjects: 0
Study 10826390 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration areas
Number of subjects: 0
Study 10826390 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration sites
Number of subjects: 0
Study 8843511 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine (2 mg; b.i.d.)
Number of subjects: 16
Study 8843511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1398498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 5 mg/kg body wt/day
Number of subjects: 9
Study 1398498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 10 mg/kg body wt/day
Number of subjects: 9
Study 1398498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 15 mg/kg body wt/day
Number of subjects: 9
Study 1398498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 20 mg/kg body wt/day
Number of subjects: 9
Study 1398498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (all doses)
Number of subjects: 9
Study 6337581 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dialysis
Number of subjects: 19
Study 6337581 — intervention group
Group type: COMPARATOR
Intervention: Sham dialysis
Number of subjects: 19
Study 6337581 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dialysis after sham dialysis
Number of subjects: 19
Study 6337581 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dialysis (second period)
Number of subjects: 19
Study 31780692 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropic nonclassicality criteria tested via homodyne detection with beam splitting operation.
Number of subjects: 0
Study 31780692 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropic nonclassicality criteria with phase randomization.
Number of subjects: 0
Study 31780692 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-mode resource states.
Number of subjects: 0
Study 30518579 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatrician-led evidence-based Falls Prevention Clinic
Number of subjects: 188
Study 30518579 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical management recommendations
Number of subjects: 188
Study 30518579 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient experience
Number of subjects: 188
Study 27091752 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (600,000 IU vitamin D3 as intramuscular injection)
Number of subjects: 0
Study 27091752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25763201 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 (200 mg/d)
Number of subjects: 52
Study 25763201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 22507468 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% tetracaine gel (Ametop gel)
Number of subjects: 15